

Simplify COVID-19 (SARS-CoV-2) testing

The BD Veritor™ Plus System

Rapid, reliable COVID-19 (SARS-CoV-2) testing at
the point of care


The portable, easy-to-use BD Veritor™ Plus System provides reliable COVID-19
(SARS-CoV-2) results in 15 minutes

For use under Interim Order Authorization only



Be ready for COVID-19 testing

When your patients are in need of fast, reliable COVID-19 testing, turn to the BD Veritor™ Plus System. Offering dependable results at the point of care, in a simple-to-operate, portable instrument.



Simplify the testing process

- Easy operation and 1-button functionality may help reduce manual test processing errors
- Simple sample processing with color-coded tubes



Achieve fast, reliable results

- Displays easy-to-read digital results for COVID-19 in 15 minutes: “CoV2: +” for positive, “CoV2: -” for negative
- Records results on secured internal drive
- Advanced particle technology helps improve test performance*



Provide workflow efficiency

- Adapts easily to your workflow by offering 2 operational modes
 - **Walk away:** Test device is inserted immediately into Analyzer, so staff can multi-task while sample incubates (15 minutes)
 - **Analyze now:** Test device is inserted after incubation time is complete, allowing batches of samples to be tested (results in seconds)



Provide result traceability

- Download and display Lot number, patient/specimen ID, Operator ID and test records with BD Veritor™ InfoScan module
- Offers result-printing capabilities via USB port

*in comparison to visually read tests

1. BD Veritor System for Rapid Detection of SARS-CoV-2 package insert. Franklin Lakes, NJ: Becton, Dickinson and Company.

BD, 2100 Derry Road West, Suite 100, Mississauga, ON, L5N 0B3
866.979.9408, customer.service.canada@bd.com

bd.com/en-ca/covid19

Clinical Performance¹

Positive Percent Agreement (PPA)	Negative Percent Agreement (NPA)
84%	100%
(95% Confidence Interval (C.I.), 67%–93%)	(95% Confidence Interval (C.I.), 98–100%)

Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.

- This test has been authorized for sale in Canada by Health Canada under Interim Order;
- This test is only authorized for the duration of the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19, unless the authorization is terminated or revoked sooner;
- This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.

Ordering information	Cat. no.	Qty.
BD Veritor™ System for Rapid Detection of SARS-CoV-2	256089	30 tests
BD Veritor™ Plus System Analyzer	256066	1

Other BD Veritor™ related products		
BD Veritor™ System Flu A+B Moderately complex	256041	30 tests
BD Veritor™ System Flu A+B CLIA-waived kit	256045	30 tests
BD Veritor™ System RSV CLIA-waived kit	256038	30 tests
BD Veritor™ System RSV Moderately complex	256042	30 tests
BD Veritor™ System Group A Strep CLIA-waived kit	256040	30 tests
BD Veritor™ InfoScan module 1	256068	1
USB printer cable 1	443907	1

